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TURNING EVIDENCE INTO PRACTICE 
Preventing drug-related deaths 
Drug misuse is a major contributor to premature mortality.1 People who use drugs are up to ten 
times more likely to die suddenly or as a result of chronic diseases than people who do not use 
drugs.2 
Many of these deaths are preventable. This document provides a checklist for services and 
local areas that want to improve their practices in this area. The content is drawn from 
published evidence, authoritative guidance, and feedback from drug treatment services. 
What is the issue? 
Recorded rates of drug-related deaths3 are higher in England than in most other European 
countries. This high number of drug-related deaths partly reflects the fact that the population of 
injecting drug users in England since the ‘epidemic’ of the 1980s is growing older. People with 
long histories of drug dependency are more likely to be in poor health and to engage in 
dangerous injecting behaviour, and are at greater risk of dying from overdose. Deaths often 
involve a combination of drugs as well as opioids, with alcohol and stimulants frequently 
mentioned on death certificates. Deaths involving new psychoactive substances (sometimes 
referred to as ‘legal highs’) have also increased in recent years. 
Preventing overdose 
Many drug overdose deaths are preventable. Ensuring appropriate practices are in place, 
along with the policies or protocols to support them, can prevent overdoses and subsequent 
fatalities. 
Enhanced treatment engagement and continuity of treatment between services and relapse 
prevention interventions can reduce the risk of overdose.4 
The substances most commonly mentioned on death certificates for overdoses are opioids, 
especially heroin. Overdose deaths mostly involve a combination of opioids and other drugs, 
such as benzodiazepines and alcohol, which can cause respiratory depression. Previous 
experience of overdose greatly increases the risk of a user dying from a later overdose. 
Injecting is particularly risky for fatal overdose. 
Users may also overdose on new psychoactive substances (NPS), as NPS tend to contain a 
mix of unknown substances that can have unpredictable effects. There are also risks when 
NPS are used in combination with alcohol and other drugs. 
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Prompts 
1. Do drug services, including needle and syringe programmes, provide service users 
with information and advice on the risk of overdose and the steps they could take to 
reduce that risk? 
2. Do staff in drug treatment services have a good understanding of high-risk practices 
(eg, injecting, polysubstance use, alcohol use), high-risk groups (eg, users who 
have previously overdosed, older users, users with certain comorbid health 
problems) and high-risk stages (eg, the initial weeks of titration on to opioid 
substitution treatment, or the weeks following exit from treatment drug-free)? Does 
this understanding inform practice on how to reduce the risk of overdose? 
3. Do services systematically assess the risk of overdose for every user attending 
structured drug treatment, and discuss with them the ways to reduce these risks? 
4. Is a range of treatment options available to reduce risk, such as rapid assessment 
and treatment engagement for those at high risk; local access to supervised 
consumption of opioid substitution treatment; support for alcohol dependence and 
alcohol detoxification; support for safer injecting practices and to stop injecting; 
information and advice? 
5. Do people leaving structured treatment have aftercare plans that include ongoing 
recovery check-ups? Is there a process for rapid re-entry to treatment and re-
stabilisation if needed? 
6. Are service users made aware of the available pathways back into treatment if they 
need to re-enter at any time? 
 
North East Council on Addictions (NECA), Darlington 
NECA works in partnership with Northern Engagement in Recovery from Addiction 
Foundation (NERAF) to deliver the Connected Recovery model. They use assertive 
outreach and assign a recovery coach to each service user to enhance engagement and 
retention, and provide peer support throughout their treatment. 
The service has regular conversations and meetings with local pharmacy staff who often 
have contact with drug users who are not in structured treatment. This gives pharmacists 
and pharmacy support staff (who have a good relationship with NECA’s lead nurse 
prescriber and service coordinator) the opportunity to discuss local practice and service 
developments, and to look at patterns of needle exchange provision and support. Hostel in-
reach services provide drug users with advice on safer injecting practices and safe storage 
of medications while overdose prevention and harm reduction workshops are provided for 
people identified as high risk, wherever they are in the treatment system. Alert systems are 
also in place if service users fail to collect medication or they are intoxicated. 
 
  
Preventing drug-related deaths 
3 
Responding to overdose 
When an overdose occurs, a rapid first aid response (including the use of naloxone) can 
reduce the risk of the user dying. Services can also give other users, friends or family members 
information and training on how to respond, as they are often close by when people overdose.  
Prompts 
1. Do services provide their staff with information and training on recognising 
overdoses, calling emergency services and delivering basic life support? 
2. Do services provide their service users and others (such as family and friends) with 
information on recognising overdose, calling emergency services and delivering 
basic life support? 
3. Do services offer overdose training and naloxone to opioid users – including those 
on opioid substitution treatment, and those leaving treatment? Do they offer this to 
their families and friends?5 
4. Do ambulance services routinely carry naloxone and are all paramedics trained to 
use it?  
5. Do local stakeholders have the opportunity to share knowledge on overdoses and 
effective responses to them? 
6. Do staff who work in local hostels used by drug users, or staff in other environments 
where overdoses may occur, have enough information and training on preventing 
and managing overdoses? 
Brighton and Hove Drug and Alcohol Action Team (DAAT) and Sussex Partnership 
NHS Foundation Trust 
Clinical records of opiate overdoses cases admitted to the Royal Sussex County Hospital 
A&E were cross-referenced with the drug and alcohol case management system. This 
highlighted that a significant proportion of A&E overdose patients were not engaged in 
treatment at the time of their overdose, so may not have had access to naloxone. 
A&E is now dispensing naloxone to overdose patients and assertive outreach is being used 
to contact former service users and help them re-engage with treatment. Many people who 
overdose on opiates are primarily alcohol users, so naloxone is now being distributed to 
selected service users in alcohol treatment. 
 
Reducing risks of prescribed medications 
Opioid substitution medicines can be diverted from treatment for misuse by people who have 
never used opioids or have inadequate tolerance to their dangerous toxic effects. Such opioid 
medicines have also on occasions poisoned children. In both circumstances fatal overdose can 
easily happen. Other medicines prescribed to drug users that might be diverted and used 
inappropriately include pain medicines (eg, opioids or pregabalin), benzodiazepines and 
antidepressants. Local areas will want to consider the adequacy of measures to limit the risk of 
diversion and misuse. 
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Prompts 
1. Do your services have agreed policies or protocols, and practices, that address: 
a. patients’ safe use of their medicines  
b. safe storage of take-home medicines (including secure containers where 
appropriate) 
c. risks of diversion to other individuals 
d. risks of poisoning children from medicines at home 
e. added risks due to polysubstance and alcohol use 
f. suitable use of supervised consumption6 
g. services providing suitable information, advice and support to reduce the 
risks 
2. Does the controlled drugs local intelligence network (CD LIN) that covers your 
commissioning area review the diversion and illicit use of opioid substitution 
treatment, other substance misuse medication, and other prescribed controlled 
drugs? 
3. Are local systems in place to support people who require access to supervised 
consumption? 
4. Are prescribing practices across your commissioning area regularly audited and 
reviewed?7 
Reducing the risk from changing settings and stages of treatment 
There is a significantly elevated risk of overdose for people in the immediate period after being 
released from prison.8 Individuals are also at risk when leaving residential rehabilitation 
programmes or inpatient treatment, after completing a drug detoxification programme,9 and 
after they stop using naltrexone.   
Important steps to take in preventing overdose at times of change including promoting and 
supporting relapse prevention, offering pathways in to (or back in to) treatment when needed, 
and providing access to suitable aftercare  
Prompts 
1. Do local services provide rapid assessment for and access to opioid substitution 
treatment, particularly for high-risk people?10 
2. Does your local partnership provide overdose awareness education for prisoners 
around the time of their release? 
3. Is there a process for rapidly transferring service users between local prison(s) and 
community-based treatment services? 
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4. Does your area have processes for providing continuity of substitute prescribing for 
released prisoners, including rapid access to community prescribing and other 
services?11 
5. Do commissioners and prison healthcare providers have arrangements to facilitate 
continuity of prescribing (particularly for opiates and benzodiazepines) for people 
who move from one area to another and after their release from prison? 
6. Do services inform users that a loss of tolerance after detoxification and exit from 
residential rehabilitation programmes or inpatient treatment can increase the risk of 
overdose and death? 
7. Do the care plans for people completing inpatient detoxification or residential 
rehabilitation incorporate transfer of care back to community services for continued 
structured treatment or for aftercare, or otherwise provide information on rapidly re-
engaging with community treatment should it be needed? 
8. After they have detoxified or left residential rehabilitation programmes or inpatient 
treatment, are patients given information on support networks and helped to engage 
with them?  
9. Do local treatment services provide recovery check-ups (via regular phone calls or 
other means) for people who have left structured treatment? Do these cover people 
whose reduced tolerance leaves them at a high risk of overdose? 
10. Do local treatment services work with other health and social care and criminal 
justice services used by drug users to identify those at risk, and to develop effective 
care pathways? 
South Tyneside NHS Foundation Trust 
South Tyneside NHS Foundation Trust Substance Misuse Service developed a care 
pathway, in consultation with staff at the Queen Elizabeth Hospital, to ensure that patients 
admitted with drug-related medical issues receive consistent advice and support in hospital 
and following their discharge to reduce the risks associated with moving between different 
settings and stages of treatment.  
 
Service staff visit the hospital each day to check for drug-related admissions. These patients 
are given harm reduction advice and information on local services, and are referred where 
appropriate. If patients are already known to staff, their substance misuse practitioner is 
notified of the admission and a visit is arranged for a welfare check within 24 hours. 
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Reducing mortality risks from delayed or chronic drug-related health 
problems 
Illicit drug use puts people at risk of developing long-term health complications that could lead 
to death. Injecting heroin, cocaine and other drugs can cause fatal conditions, such as the 
complications of deep vein thrombosis (DVT), serious tissue infections, blood-borne and other 
viral infections (particularly hepatitis C and B infections and HIV). Smoking drugs such as 
crack, heroin and tobacco can lead to life-threatening respiratory and cardiovascular disease. 
Fatal liver disease can arise from a combination of excessive alcohol use, polydrug use and 
viral hepatitis infection. 
Prompts 
1. Do services offer confidential testing for hepatitis C and HIV to all people who use 
drugs, including those currently injecting and or who previously injected drugs? 
2. Do services promote testing and vaccination for hepatitis B virus infection? 
3. Do services facilitate appropriate pre and post-test discussion with users about 
blood-borne virus infections and HIV, including the options for treatment referral?  
4. Do services provide safer injecting advice to reduce the risk of local tissue damage 
and associated serious infections, deep vein thrombosis (DVT) and its 
complications, and the risks of contracting blood-borne virus infections through 
sharing needles, syringes or other drugs paraphernalia? 
5. Do services give users information about the wider health harm associated with 
their drug use, including the respiratory and cardiovascular risks from smoking? 
6. Do services provide advice on the long-term risks of polydrug and alcohol use? 
7. Do services provide advice, referral and treatments to help users stop smoking? 
Wirral Harm Reduction Unit 
Safer injecting advice is given while users attend the syringe exchange and at a weekly safe 
injecting clinic. This advice covers observation and palpation of existing and previous 
injecting sites, type of equipment used, process of injecting (including sterilising equipment), 
problem solving when injecting ‘goes wrong’ (missed hits and no access), maintaining 
healthy sites by keeping them clean and accessible, recognising infected sites and their 
symptoms, and when rectal administration might be appropriate. 
 
The safe injecting clinic relays alerts when contaminated heroin warnings are confirmed, 
provides blood-borne virus screenings, and facilitates access to other services (eg, sexual 
health). 
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Reducing mortality risks from new psychoactive substance and volatile 
substances 
New psychoactive substances (NPS) and volatile substances can cause a wide range of 
harmful health effects and sometimes fatalities. 
Drug services need to offer information and advice to users and other services on the effects 
and risks of these substances, and on how to reduce the risks. Other relevant services may 
also need to provide information and advice to NPS users. Services will want to keep abreast 
of information on local NPS use and prevalence and on volatile substance abuse. Developed 
systems for collecting, evaluating and disseminating information on new drugs and their harm 
can help local management of such risks (see ‘Using local early warning systems and alert 
systems to enhance provision’ below). These new substances are often used by people who 
do not form part of traditional treatment service groups.12 
Prompts 
1. Is information available in drug services, schools and youth services about the 
effects and risks and legal status of NPS and volatile substances for both staff and 
service users; and, in appropriate local services, for young people and their 
parents? Is this information regularly updated? 
2. Do relevant partners (including drug treatment services, community youth groups 
and schools) work together to identify, respond and construct a coordinated 
response to the impact of local retail outlets which specialise in drug paraphernalia 
and legal highs (‘head shops’)?13   
3. Do services provide advice on the particular risks of mixing stimulant substances 
with depressants (such as opioids, benzodiazepines and alcohol), and the risks of 
mixing multiple stimulants? 
4. Does your local commissioning area have outreach services for young people that 
promote safer, healthier attitudes to reduce the risk from drug-taking behaviour in 
nightclubs? 
5. Do relevant services give advice on how to reduce risk among those who abuse 
volatile substances? 
6. Do services provide NPS users with information on more-specialised services and 
help them to access these services? Do they also host additional in-reach support? 
7. Do the available services deliver advice and support to local NPS users who may 
not form part of traditional treatment service groups or who present with specific 
needs (such as ‘clubbers’, men who have sex with men, students, travellers or sex 
workers)?  
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Club Drug Clinic, Central and North West London NHS Foundation Trust 
The Club Drug Clinic offers medically assisted withdrawal from substances and a range of 
community and in-patient detoxes, including polysubstance drug and alcohol detoxes and 
GHB/GBL detoxifications. The clinic also prescribes medication to aid stimulant withdrawal. 
Advice and support is provided by specialist addiction doctors and psychologists, nurses, 
counsellors, and peer mentors who have ’lived experience’ and overcome similar problems.  
 
On-site sexual health screening and support is available, as are liaison and referral for 
mental and physical health problems (including bladder and kidney, and HIV and other 
blood borne viruses). 
 
Using local reviews of drug-related deaths to enhance provision 
A robust review process that encourages different agencies to work together can help local 
areas learn more about the events leading up to drug-related deaths. It can also lead to 
suitable measures that might reduce the risk in future.14 
This review process is commonly done through local providers’ governance systems that 
incorporate drug-death reviews, or through partnership-level confidential inquiries of deaths 
(both processes involve specific evidence-gathering and analysis). Reviews can also be based 
on an ongoing analysis of statistical data and characteristics of local drug deaths over time. 
Prompts 
1. Does your local commissioning area have a system for identifying drug-related 
deaths? 
2. Does your local commissioning area have an effective system for examining and 
learning lessons from drug-related deaths and for taking relevant action? 
3. Does your local area have a system for reporting the outcome of local examinations 
of drug-related deaths? 
4. Does your local area have a system for monitoring numbers and characteristics of 
drug deaths over time? 
5. Does your local area have a common and consistent definition of ‘drug-related 
deaths’ for reporting and monitoring across agencies? 
6. Are incidents of non-fatal overdose or ‘near misses’ fed into the confidential inquiry 
or drug-death review process? 
7. Is there a link between the local drug-death review group and the corresponding 
controlled drugs local intelligence network (CD LIN)? 
8. Are prescription opioid deaths reviewed as part of the local drug-related deaths 
review process? 
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Devon, Cornwall, Plymouth and Torbay Drug Action Teams 
A south-west peninsula-wide database was introduced following liaison between Devon, 
Cornwall, Plymouth and Torbay, together with Devon and Cornwall police. Drug-related 
death information is shared by all the agencies a drug-user may have been in contact with. 
The coroner’s close involvement means the group receives toxicology results within six 
weeks, and uses that information to identify patterns of deaths and to inform future action. 
 
One case highlighted a breakdown in communication between the probation service and 
Cornwall treatment services. Since then, the probation and treatment service boundaries 
have been aligned and cover the same geographical areas. This has improved 
communication. 
 
Using local early warning and alert systems to enhance provision 
Local early warning and alert systems can quickly identify and share information about 
contaminated and adulterated drugs, changes in strength and formulation, new substances, 
and changing trends in substance use. Effective systems assess the quality of intelligence 
coming in and the levels of likely harm, and disseminate information accordingly without 
causing unnecessary alarm or information overload. 
Prompts 
1. Do local services and commissioning areas have a system for receiving and acting 
on national, regional or local reports of potentially dangerous substances or 
practices? 
2. Are there clear points of contact for such alerts? 
3. Is there effective local partnership working in an agreed system of process and 
paperwork that enables partnerships and treatment services to verify and assess 
intelligence about drug dangers? 
4. Do local early warning and alert systems use standardised formats to record and 
process intelligence and to distribute information systematically? Does this include 
confirmed alerts?15 
5. Do treatment and other services participate in local intelligence networks and have 
other mechanisms in place to exchange information with and disseminate advice to 
staff, service users and other health and social care and criminal justice services? 
6. Is information from early warning and alert systems shared with local confidential 
inquiry or drug-death review processes? 
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Southampton Drug Action Team 
Southampton Drug Action Team created a drug warning partnership. The local service user 
advocacy service, MORPH (part of Southampton Voluntary Services), works as a single 
point of contact to maintain a local, centralised and collaborative approach, which ensures 
quality and trust in the dissemination of important information. 
 
When a drug warning is received by any drug warning partnership participant, this 
information is sent to MORPH. They then consult with appropriate partners to check the 
accuracy and relevance of the warning and consider the impact of further action. A 
consensus among the partnership is then agreed. If necessary MORPH designs, publishes 
and disseminates a warning to all partners for display in their services. This ensures reliable 
messages are presented in a consistent way. 
 
Other briefings in the ‘Turning evidence into practice’ series: 
 Helping service users to access and engage with mutual aid [NTA, 2013] 
 Helping service users to engage with treatment and stay the course [PHE, 2013] 
 Biological testing in drug and alcohol treatment [PHE, 2013] 
 Optimising opioid substitution treatment [PHE, 2013] 
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